Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies
出版年份 2022 全文链接
标题
Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies
作者
关键词
-
出版物
BIOMEDICINE & PHARMACOTHERAPY
Volume 158, Issue -, Pages 114174
出版商
Elsevier BV
发表日期
2022-12-31
DOI
10.1016/j.biopha.2022.114174
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Breaking Through the Therapeutic Ceiling: What Will It Take?
- (2022) Tim Raine et al. GASTROENTEROLOGY
- COMBINATION BIOLOGIC AND SMALL MOLECULE THERAPY FOR REFRACTORY ULCERATIVE COLITIS
- (2022) Kaitlyn Hickman et al. INFLAMMATORY BOWEL DISEASES
- Elective Switching on Biosimilars: Far More Than Nonmedical Switching
- (2022) Xiaocang Cao et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
- (2022) Konstantinos Papamichael et al. Lancet Gastroenterology & Hepatology
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
- (2022) Silvio Danese et al. LANCET
- Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
- (2022) Geert D'Haens et al. LANCET
- Emerging pharmacotherapy for inflammatory bowel diseases
- (2022) Hua Luo et al. PHARMACOLOGICAL RESEARCH
- AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2022) Katsuyoshi Matsuoka et al. Lancet Gastroenterology & Hepatology
- Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status
- (2021) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab (SHP647) for the treatment of ulcerative colitis: the open-label study TURANDOT II
- (2021) Walter Reinisch et al. Journal of Crohns & Colitis
- A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study
- (2021) Irene Marafini et al. BIODRUGS
- Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
- (2021) Waseem Ahmed et al. Clinical Gastroenterology and Hepatology
- Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease
- (2021) Carlos Stalgis et al. GASTROENTEROLOGY
- An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective
- (2021) Carsten Schmidt et al. Frontiers in Pharmacology
- Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy
- (2021) Giuseppe Privitera et al. AUTOIMMUNITY REVIEWS
- Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn’s disease in children
- (2021) Gadi Howard et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases
- (2021) Quazim A Alayo et al. INFLAMMATORY BOWEL DISEASES
- Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study
- (2021) Geert R D’Haens et al. INFLAMMATORY BOWEL DISEASES
- The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
- (2021) Patricia Gogesch et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
- (2021) Brian G Feagan et al. LANCET
- Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera
- (2021) Marten Beeg et al. Scientific Reports
- Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery
- (2021) Lu Tang et al. Pharmaceutics
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease
- (2021) Bruce E. Sands et al. GASTROENTEROLOGY
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
- (2021) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
- (2021) Daniel C. Baumgart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
- (2021) David T Rubin et al. Lancet Gastroenterology & Hepatology
- Combination Biologic Therapy in Inflammatory Bowel Disease: Experience from a Tertiary Care Center
- (2020) Lukasz Kwapisz et al. Clinical Gastroenterology and Hepatology
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
- (2020) William J. Sandborn et al. ADVANCES IN THERAPY
- Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease
- (2020) Edward Yang et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Double Biologic Therapy for Refractory Stricturing Crohn’s Disease: A Successful Case of Deep Remission with Ustekinumab and Vedolizumab
- (2020) Ahmed Elmoursi et al. INFLAMMATORY BOWEL DISEASES
- Dual‐targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease
- (2020) Marta Vernero et al. JOURNAL OF DERMATOLOGY
- JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
- (2020) Azucena Salas et al. Nature Reviews Gastroenterology & Hepatology
- Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature
- (2020) Christine Olbjørn et al. PEDIATRIC DRUGS
- Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor in Patients with Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2020) Michael F. Robinson et al. Arthritis & Rheumatology
- Letter: combination of biologics in inflammatory bowel diseases
- (2020) Mathurin Fumery et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
- (2020) Brian G Feagan et al. Lancet Gastroenterology & Hepatology
- S0707 The Use of Combination Vedolizumab and Ustekinumab in Crohn's Disease: A Retrospective Cohort Study
- (2020) Kerri Glassner et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab
- (2020) Giuseppe Biscaglia et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?
- (2020) Marjorie Argollo et al. Nature Reviews Gastroenterology & Hepatology
- It Takes Two to Make It Right: Dual Biologic and Small Molecule Therapy for Treatment-Refractory Pediatric Inflammatory Bowel Disease
- (2020) Duke Geem et al. INFLAMMATORY BOWEL DISEASES
- Pathophysiology of Inflammatory Bowel Diseases
- (2020) John T. Chang NEW ENGLAND JOURNAL OF MEDICINE
- Infliximab paradoxical psoriasis in a cohort of children with inflammatory bowel disease
- (2019) Olivier Courbette et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- P718 Risk of tuberculosis in patients with inflammatory bowel disease receiving biologics using two interferon-γ release assays as monitoring
- (2019) R de Francisco et al. Journal of Crohns & Colitis
- Mo1906 – Combination Therapy of Vedolizumab and Tofacitinib in IBD Patients with Chronic Active Refractory Disease Course and Spondylarthritis
- (2019) Tanja Kuehbacher et al. GASTROENTEROLOGY
- Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis
- (2019) Davide Giuseppe Ribaldone et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
- (2019) Konstantinos Papamichael et al. Expert Review of Clinical Immunology
- IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease
- (2019) Stephen B Hanauer et al. Journal of Crohns & Colitis
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- P012 Successful Use of Combination Biologic Therapy in Medically Refractory Pediatric Crohnʼs Disease and Sacroiliitis
- (2019) Julie Bass et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Mongersen (GED-0301) for Active Crohnʼs Disease
- (2019) Bruce E. Sands et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists
- (2018) Hiroki Mitoma et al. CYTOKINE
- Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
- (2018) Heike Schmitt et al. GUT
- Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
- (2018) Lydia C T Buer et al. INFLAMMATORY BOWEL DISEASES
- Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy
- (2018) Catherine Le Berre et al. Clinical Gastroenterology and Hepatology
- Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies
- (2018) Laurent Peyrin-Biroulet et al. AUTOIMMUNITY REVIEWS
- Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis
- (2018) William J. Sandborn et al. GASTROENTEROLOGY
- IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
- (2018) Alexander R. Moschen et al. Nature Reviews Gastroenterology & Hepatology
- Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease
- (2017) Brigid S. Boland et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
- (2017) Silvio Danese et al. GUT
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohnʼs Disease
- (2017) Kayci Huff-Hardy et al. INFLAMMATORY BOWEL DISEASES
- Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy
- (2017) Xavier Roblin et al. Journal of Crohns & Colitis
- P514 Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data
- (2017) L. Buer et al. Journal of Crohns & Colitis
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transmembrane TNF-alpha reverse signaling leading to TGF-beta production is selectively activated by TNF targeting molecules: Therapeutic implications
- (2017) Zsuzsa Szondy et al. PHARMACOLOGICAL RESEARCH
- Novel Targeted Therapies for Inflammatory Bowel Disease
- (2017) Mehmet Coskun et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
- (2016) G. Monteleone et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
- (2016) Clara Yzet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
- (2016) Caroline Meyer Olesen et al. PHARMACOLOGY & THERAPEUTICS
- Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease
- (2015) Robert Hirten et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges
- (2015) Irene Marafini et al. DRUGS
- IL-6 as a keystone cytokine in health and disease
- (2015) Christopher A Hunter et al. NATURE IMMUNOLOGY
- TNF biology, pathogenic mechanisms and emerging therapeutic strategies
- (2015) George D. Kalliolias et al. Nature Reviews Rheumatology
- Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
- (2014) Stanley Cohen et al. Arthritis & Rheumatology
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
- (2013) Ying He et al. BMC MUSCULOSKELETAL DISORDERS
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
- (2013) Mehmet Coskun et al. PHARMACOLOGICAL RESEARCH
- Tumor necrosis factor
- (2012) Wen-Ming Chu CANCER LETTERS
- Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children
- (2012) Jeffrey S. Hyams et al. GASTROENTEROLOGY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
- (2012) Luke Jostins et al. NATURE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review article: remission rates achievable by current therapies for inflammatory bowel disease
- (2011) L. Peyrin-Biroulet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Certolizumab Pegol: A TNF-α Antagonist for the Treatment of Moderate-to-Severe Crohn's Disease
- (2010) Lisa S Smith et al. ANNALS OF PHARMACOTHERAPY
- Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
- (2010) Mark E. Flanagan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sphingosine 1-Phosphate Receptor Signaling
- (2009) Hugh Rosen et al. Annual Review of Biochemistry
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules
- (2009) David Marsolais et al. NATURE REVIEWS DRUG DISCOVERY
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and Prediction
- (2008) Mark Wing Journal of Immunotoxicology
- TNF-mediated inflammatory disease
- (2007) JR Bradley JOURNAL OF PATHOLOGY
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now